文献速递淋巴瘤血栓与止血

PET/CT得出的冠状动脉钙化评分可预测接受蒽环类药物治疗的淋巴瘤患者的心脏并发症

PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

研究纳入2012至2022年间接受蒽环类化疗的358例连续淋巴瘤患者,从治疗前PET/CT计算冠状动脉钙化评分(CACS)。中位随访27个月(95%CI 22.3-31.7),无心脏病史者10%发生治疗后心脏事件;CACS>0者事件更多(20% vs 5.4%,P<.001)。CACS升高与心衰及任意心脏事件独立相关。

要点

  • 治疗前PET/CT可计算CACS,用于淋巴瘤患者心脏事件风险分层。
  • CACS>0者治疗后心脏事件20%,CACS=0者5.4%(P<.001)。
  • CACS 1-400与心衰相关OR 3.73,CACS>400与心衰相关OR 5.43。

核心结论

  • CACS可能有效分层淋巴瘤患者心脏并发症风险,从而识别可从靶向预防策略中获益的人群。

研究设计与样本

  • 研究纳入2012至2022年间接受蒽环类化疗的358例连续淋巴瘤患者,从治疗前PET/CT计算CACS。
  • 回顾病历识别既存心脏疾病、心血管风险(CVR)及治疗后心脏事件(冠状动脉事件、心衰、心律失常)。
  • 采用逻辑回归和Cox回归模型评估CVR、CACS分类(CACS=0、CACS 1-400、CACS>400)与新发心脏事件之间的关联。

主要发现

  • 无心脏病史患者中位随访27个月(95%CI 22.3-31.7),10%发生治疗后心脏事件(心衰14例、心律失常9例、冠状动脉事件1例、组合8例)。
  • CACS>0者心脏事件共21例(20%),CACS=0者共11例(5.4%),P<.001。
  • CACS 1-400与心衰独立相关(OR 3.73;95%CI 1.21-11.43;P=.022),CACS>400与心衰独立相关(OR 5.43;95%CI 1.47-20.03;P=.011)。
  • CACS 1-400与任意心脏事件相关(OR 2.48;95%CI 1.02-6.04;P=.045),CACS>400与任意心脏事件相关(OR 3.28;95%CI 0.91-10.68;P=.029)。

关键数值与推荐

  • CACS分类阈值:CACS=0、CACS 1-400、CACS>400。
  • CACS 1-400与心衰的OR 3.73(95%CI 1.21-11.43;P=.022)。
  • CACS>400与心衰的OR 5.43(95%CI 1.47-20.03;P=.011)。
  • CACS 1-400与任意心脏事件的OR 2.48(95%CI 1.02-6.04;P=.045)。
  • CACS>400与任意心脏事件的OR 3.28(95%CI 0.91-10.68;P=.029)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anthracycline-mediated cardiotoxicity is a common concern after lymphoma therapy, particularly in patients with high cardiovascular risk (CVR). In noncancer populations, coronary artery calcium scoring (CACS) effectively identifies individuals who may benefit from aggressive CVR modification to lower the risk of cardiovascular events. Emerging evidence suggests that CACS can also predict cancer therapy-related cardiotoxicity, potentially identifying candidates for cardioprotective strategies. Our study aimed to evaluate whether CACS obtained from pretreatment positron emission tomography (PET)/computed tomography (CT) scans could stratify cardiac event risk in patients with lymphoma receiving anthracycline-based chemotherapy. We enrolled 358 consecutive patients with lymphoma treated between 2012 and 2022, calculating the CACS from their pretreatment PET/CT. We reviewed medical records to identify pre-existing cardiac conditions, CVR, and posttreatment cardiac events, including coronary events, heart failure (HF), and arrhythmias. Logistic and Cox regression models were used to assess associations between CVR, CACS categories (CACS = 0, CACS 1-400, CACS >400), and new cardiac events. At a median follow-up of 27 months (95% confidence interval [CI], 22.3-31.7) in patients without cardiac history, 10% experienced posttreatment cardiac events (HF, 14; arrhythmias, 9; coronary event, 1; combination, 8). Patients with a CACS >0 had more events (21 total, 20% vs 11 total, 5.4% for CACS = 0; P < .001). Elevated CACS was independently associated with HF (CACS 1-400: odds ratio [OR], 3.73; 95% CI, 1.21-11.43; P = .022; CACS >400: OR, 5.43; 95% CI, 1.47-20.03; P = .011) and any cardiac event (CACS 1-400: OR, 2.48; 95% CI, 1.02-6.04; P = .045; CACS >400: OR, 3.28; 95% CI, 0.91-10.68; P = .029). CACS may effectively stratify patients with lymphoma at risk of cardiac complications, thereby identifying a group poised to benefit from targeted preventive strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Douglas G, Loh Z, Shum ESY, et al. PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma. Blood Adv. 2025. PMID: 39576964. doi:10.1182/bloodadvances.2024013620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。